Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434993 · ClinicalTrials.gov registry record · Phase 2
Drug Study of Albuterol to Treat Acute Lung Injury
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00434993 is a Phase 2 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 282 participants.
The verdict
NCT00434993, a Phase 2 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.
Interventions
- DRUG Placebo
- DRUG Albuterol Sulfate
- PROCEDURE Mini-Bronchoalveolar Lavage (BAL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00434993
The ClinicalTrials.gov registry entry for NCT00434993 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00434993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00434993 about?
NCT00434993 is a clinical study titled "Drug Study of Albuterol to Treat Acute Lung Injury". Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these...
What is the current status of trial NCT00434993?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2007-08. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00434993?
The interventions under investigation include: Placebo (DRUG), Albuterol Sulfate (DRUG), Mini-Bronchoalveolar Lavage (BAL) (PROCEDURE).
Who is sponsoring clinical trial NCT00434993?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.